Prognostic significance of PCR-based measurable residual disease post-induction and during consolidation in pediatric KMT2A-rearranged acute myeloid leukemia
Blood-based disease monitoring during childhood leukemia treatment independently predicts relapse risk, helping guide transplant decisions for high-risk patients.
In 46 pediatric patients with KMT2A-rearranged AML, PCR-based MRD monitoring during induction and consolidation provided critical independent prognostic information, with post-consolidation PCR-MRD positivity strongly predicting inferior overall survival and cumulative relapse risk. These findings support integration of PCR-MRD into risk stratification to guide allo-HSCT decisions in this high-risk pediatric AML subtype.
What the study was
- Study design
- Retrospective cohort (prospectively registered)
- Population
- Pediatric patients with KMT2A-rearranged acute myeloid leukemia
- Sample size
- 46
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Leukemia Research
Why it surfaced
Pediatric KMT2A-r AML is a high-risk subtype with high unmet need; PCR-MRD adds granularity beyond flow cytometry for risk stratification; prospectively registered (ChiCTR1900027146); small n=46 caps design quality
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.